MedPath

Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina

Phase 4
Completed
Conditions
Myocardial Ischemia
Registration Number
NCT00143195
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Brief Summary

The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Outpatients > =18 years of age with diagnosed clinically stable angina pectoris
Exclusion Criteria
  • Patients with congestive heart failure, clinically significant cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Evaluate the time to 1mm ST depression
Secondary Outcome Measures
NameTimeMethod
The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety

Trial Locations

Locations (1)

Pfizer Investigational Site

🇬🇷

Zakynthos, Greece

© Copyright 2025. All Rights Reserved by MedPath